Europe’s top drug-safety panel formally tied semaglutide to a very rare risk of sudden vision loss, and the rest of the world is now catching up.
Story Snapshot
- European regulators added a “very rare” NAION warning to semaglutide products Ozempic, Rybelsus, and Wegovy.
- The World Health Organization alerted doctors and regulators worldwide to the same risk signal.
- Federal lawsuits over GLP-1–related vision loss are consolidated in a multidistrict case with hundreds of claims.
- Large studies report a small but measurable rise in NAION risk for some semaglutide users, though debate continues.
What Regulators Have Already Decided
The European Medicines Agency’s safety committee reviewed lab data, trial data, real-world reports, and medical papers. It concluded non-arteritic anterior ischemic optic neuropathy, or NAION, is a very rare side effect of semaglutide.
It recommended label updates for Ozempic, Rybelsus, and Wegovy across the European Union. The World Health Organization then issued a global alert urging clinicians and health officials to watch for NAION in patients on these same medicines and echoed the “very rare” label.
These decisions did not pull the drugs from use. They told prescribers and patients to know the symptoms and act fast if vision changes occur. That approach fits drug safety reality.
Very rare risks can be real and important without wiping out the major health gains these medicines bring. The signal is official in Europe and flagged worldwide, which sets the floor for any serious discussion about risk management.
What The Lawsuits Claim And Where They Stand
Hundreds of people now claim they suffered sudden, often permanent vision loss after using Ozempic, Wegovy, or other glucagon-like peptide-1 drugs. Federal cases are grouped in a single court under a multidistrict litigation process.
That structure speeds shared discovery and early test cases, which is standard when a new drug-safety dispute scales up. National media have profiled plaintiffs who say life changed overnight, from leaving jobs to losing the ability to drive or read.
Manufacturers deny wrongdoing and say the claims lack proof. They argue the benefits remain strong, that NAION is rare with many risk factors, and that their own trial reviews showed no harmful imbalance. They also stress active safety monitoring.
Those points will matter in court, but they do not erase what European regulators already placed on the label. The legal fight now turns on timing, warning language, and individual medical proof.
What The Science Signals Right Now
Two kinds of evidence shape this debate. First, pharmacovigilance and regulator review can justify a warning when the balance of data supports a rare link. That is what happened in Europe. Second, observational studies estimate how much the risk rises and in whom.
A very large matched-cohort analysis found a small but statistically significant increase in NAION among glucagon-like peptide-1 users over five years. The absolute risk difference was tiny, but real in the dataset.
Dozens of Americans have filed personal injury lawsuits against the makers of popular GLP-1 drugs, like Ozempic, Wegovy and Mounjaro, claiming they were not properly warned of the risk of a rare type of sudden vision loss.
Read more: https://t.co/8Ya6IBINiL pic.twitter.com/LZLdQltf28
— ABC News (@ABC) September 22, 2026
A recent meta-analysis reported low-to-moderate certainty evidence that semaglutide raises NAION risk compared to non–glucagon-like peptide-1 options, with the signal stronger in diabetes.
The authors called for more study and for doctors to discuss the risk with patients. That is a sober, middle-lane view: keep the benefits, add awareness, and act fast if warning signs appear.
What Patients And Doctors Should Do Next
Patients should not stop medicine without talking to their doctor. They should learn NAION’s early clues: sudden vision dimming, a dark spot, loss of side vision, or a drop in color vision in one eye. Anyone with these symptoms should seek urgent eye care the same day.
Doctors should document baseline vision, counsel on red-flag symptoms, and revisit therapy choice for patients with past NAION or tight optic nerves. That is common-sense risk control, not panic.
Choice still depends on the person. Someone with type 2 diabetes and heart risks may gain large benefits from semaglutide, which can outweigh a very rare eye risk. Another patient with prior NAION or crowded optic nerves may pick a different path.
Bottom Line For GLP-1 Users
Europe has put NAION on the semaglutide label. The World Health Organization has raised a global flag. Large studies show a small increase in NAION risk for some users, while companies dispute causation and emphasize benefits.
Patients should stay the course with eyes open—literally and figuratively. Know the warning signs, call fast if they appear, and press your care team for a plan that protects both your vision and your long-term health.
Sources:
usatoday.com, seegerweiss.com, dra.gov.pk, harmreport.com, who.int, aifa.gov.it, news.sbs.co.kr, callfob.com
